Iovance Biotherapeutics, Inc.(IOVA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IOVA Iovance Biotherapeutics, Inc.

未开盘 08-19 16:00:00 EDT

7.99

+0.96

+13.66%

盘后8.04

+0.05+0.61%

19:59 EDT

最高8.06	最低7.19	成交量2,425万
今开7.20	昨收7.03	日振幅12.30%
总市值36.19亿	流通市值31.48亿	总股本4.53亿
成交额1.87亿	换手率6.15%	流通股本3.94亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IOVA","market":"US","secType":"STK","nameCN":"Iovance Biotherapeutics, Inc.","latestPrice":7.99,"timestamp":1787169600000,"preClose":7.03,"halted":0,"volume":24248267,"hourTrading":{"tag":"盘后","latestPrice":8.0385,"preClose":7.99,"latestTime":"19:59 EDT","volume":371941,"amount":2974436.9506,"timestamp":1787183981485,"change":0.0485,"changeRate":0.00607,"amplitude":0.012516},"delay":0,"changeRate":0.13655761024182075,"floatShares":394000000,"shares":452971432,"eps":-0.705789,"marketStatus":"未开盘","change":0.96,"latestTime":"08-19 16:00:00 EDT","open":7.2,"high":8.055,"low":7.19,"amount":186607485.344968,"amplitude":0.123044,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.705789,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1787212800000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":7.03,"preHourTrading":{"tag":"盘前","latestPrice":7.2,"preClose":7.03,"latestTime":"09:29 EDT","volume":994731,"amount":6807626.220573599,"timestamp":1787146199999,"change":0.17,"changeRate":0.024182,"amplitude":0.102418},"postHourTrading":{"tag":"盘后","latestPrice":8.0385,"preClose":7.99,"latestTime":"19:59 EDT","volume":371941,"amount":2974436.9506,"timestamp":1787183981485,"change":0.0485,"changeRate":0.00607,"amplitude":0.012516},"volumeRatio":1.684932,"impliedVol":1.1011,"impliedVolPercentile":0.6454},"requestUrl":"/m/hq/s/IOVA","defaultTab":"news","newsList":[{"id":"1107208733","title":"异动解读｜Iovance Biotherapeutics盘中上涨10.03%，Q2业绩大超预期延续上行动能","url":"https://stock-news.laohu8.com/highlight/detail?id=1107208733","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107208733?lang=zh_cn&edition=full","pubTime":"2026-08-20 01:13","pubTimestamp":1787159599,"startTime":"0","endTime":"0","summary":"8月20日，Iovance Biotherapeutics盘中上涨10.03%，报7.735美元/股，成交额1.04亿美元。强劲的商业化表现推动股价在财报发布后持续走强，当前仍处于业绩驱动的上行通道中。Iovance Biotherapeutics是一家专注于自体肿瘤浸润淋巴细胞疗法开发与商业化的生物技术公司，主要用于治疗转移性黑色素瘤等实体瘤。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145971348","title":"Iovance Biotherapeutics 公布2026年第二季度创纪录营收约9900万美元，并披露业务进展及公司动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1145971348","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145971348?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:02","pubTimestamp":1786014141,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics（IOVA）近日发布了2026年第二季度的财务报告与业务更新。数据显示，该公司该季度营收飙升至约9900万美元，创下历史新高。与此同时，公司还披露了多项关键业务成就与战略调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105191515","title":"Iovance Biotherapeutics 提交补充招股书，拟增发普通股筹资上限约8970万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1105191515","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105191515?lang=zh_cn&edition=full","pubTime":"2026-06-19 04:35","pubTimestamp":1781814938,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics公司已提交了一份销售协议补充招股说明书，计划增发普通股，最高筹资额约为8970万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126068070","title":"Iovance公司Amtagvi® (Lifileucel)获澳大利亚批准用于治疗晚期黑色素瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1126068070","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126068070?lang=zh_cn&edition=full","pubTime":"2026-06-04 04:05","pubTimestamp":1780517115,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics公司旗下产品Amtagvi® (Lifileucel)已获得澳大利亚监管机构的批准，用于治疗晚期黑色素瘤。这一进展标志着该细胞疗法在拓展全球市场准入方面迈出了关键一步，为当地晚期黑色素瘤患者提供了一种新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195027615","title":"Iovance Biotherapeutics 公布2026年第一季度积极业绩、业务成就及公司最新动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1195027615","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195027615?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:07","pubTimestamp":1778152054,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics 重点展示了其2026年第一季度的积极财务业绩、取得的重大业务成就以及重要的公司进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113419522","title":"财报前瞻｜Iovance Biotherapeutics, Inc.本季度营收预计小幅下滑，看多观点占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1113419522","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113419522?lang=zh_cn&edition=full","pubTime":"2026-04-30 14:38","pubTimestamp":1777531119,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics, Inc.将于2026年05月07日发布财报。市场一致预期本季度Iovance Biotherapeutics, Inc.营收为7,839.63万美元，同比下降4.05%；调整后每股收益为-0.15美元，同比改善37.43%；息税前利润为-6,667.17万美元，同比改善16.71%。公司上季度财报未给出对本季度的明确收入预测指引。公司当前主营业务亮点集中在“产品”业务，上季度收入为2.64亿美元。从近半年公开资料梳理的机构表述看，看多观点占优。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜Iovance Biotherapeutics, Inc.本季度营收预计小幅下滑，看多观点占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125480549","title":"异动解读 | TIL疗法临床试验获积极结果，Iovance Biotherapeutics盘中大涨22.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=1125480549","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125480549?lang=zh_cn&edition=full","pubTime":"2026-02-24 22:49","pubTimestamp":1771944590,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics, Inc.今日盘中大涨22.44%，引起了市场的广泛关注。消息面上，公司近日宣布，其针对软组织肉瘤的肿瘤浸润淋巴细胞疗法在首次临床试验中取得了积极成果。这一突破性进展标志着TIL细胞疗法在实体瘤治疗领域迈出了关键一步，为患者带来了新的治疗希望，也显著增强了投资者对公司研发管线未来潜力的信心。这些积极的临床数据和研发进展共同构成了推动股价在盘中交易中强劲上扬的主要动力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109894775","title":"异动解读 | 软组织肉瘤TIL疗法临床试验获积极结果，Iovance Biotherapeutics盘前大涨9.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109894775","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109894775?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:13","pubTimestamp":1771935202,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics, Inc.今日盘前股价大幅上涨9.34%，引起了市场的广泛关注。消息面上，公司近日宣布，其针对软组织肉瘤的肿瘤浸润淋巴细胞疗法在首次临床试验中取得了积极成果。这一突破性进展标志着TIL细胞疗法在实体瘤治疗领域迈出了关键一步，为患者带来了新的治疗希望，也显著增强了投资者对公司研发管线未来潜力的信心。这些积极的临床数据共同构成了推动股价在盘前交易中强劲上扬的主要动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181075973","title":"Iovance Biotherapeutics公司计划于2026年第二季度启动针对二线晚期UPS和DDLPS的单臂注册试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1181075973","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181075973?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:12","pubTimestamp":1771935155,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics公司近日宣布，计划于2026年第二季度启动一项单臂注册临床试验。该试验将针对二线治疗后的晚期未分化多形性肉瘤和去分化脂肪肉瘤患者展开。试验时间的确定基于公司对研发管线进度的综合评估。2026年第二季度这一时间点，既考虑了临床前研究的成熟度，也兼顾了监管沟通的时间需求。单臂试验设计的采用，有望在保证科学严谨性的同时，加快潜在疗法的可及性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179080118","title":"Iovance Biotherapeutics, Inc.：Lifileucel疗法的安全性特征良好且与其他适应症一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1179080118","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179080118?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:11","pubTimestamp":1771935096,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics, Inc.公布的数据显示，其核心疗法Lifileucel展现出良好的安全性特征。这一安全性与该疗法在其他适应症中观察到的数据保持一致，进一步支持了其潜在的治疗价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164686652","title":"Iovance公布软组织肉瘤TIL细胞疗法首次临床试验积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1164686652","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164686652?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:11","pubTimestamp":1771935082,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics公司近日宣布，其针对软组织肉瘤的肿瘤浸润淋巴细胞（TIL）疗法在首次临床试验中取得积极成果。该突破性进展标志着TIL细胞疗法在实体瘤治疗领域迈出关键一步，为软组织肉瘤患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517189430","title":"Iovance Biotherapeutics, Inc.2024财年实现净利润-3.72亿美元，同比增加16.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517189430","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517189430?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363251,"startTime":"0","endTime":"0","summary":"3月8日，Iovance Biotherapeutics, Inc.公布财报，公告显示公司2024财年净利润为-3.72亿美元，同比增加16.22%；其中营业收入为1.64亿美元，同比增加13681.51%，每股基本收益为-1.28美元。从资产负债表来看，Iovance Biotherapeutics, Inc.总负债2.00亿美元，其中短期债务12.90百万美元，资产负债比为4.55，流动比率为3.75。机构评级：截至2025年3月8日，当前有13家机构对Iovance Biotherapeutics, Inc.目标价做出预测，其中目标均价为20.54美元，其中最低目标价为6.00美元，最高目标价为32.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000219a2647f65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000219a2647f65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517237539","title":"Iovance Biotherapeutics, Inc.盘中异动 下午盘股价大涨5.03%报4.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517237539","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517237539?lang=zh_cn&edition=full","pubTime":"2025-03-06 03:22","pubTimestamp":1741202536,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日03时22分，Iovance Biotherapeutics, Inc.股票出现波动，股价快速上涨5.03%。Iovance Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为2.06%。Iovance Biotherapeutics, Inc.公司简介：Iovance Biotherapeutics Inc 是一家临床阶段的生物制药公司，通过利用人体免疫系统识别和摧毁多种癌细胞的能力，为每位患者提供个性化治疗，开创了治疗癌症的变革性方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306032216963b1b32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306032216963b1b32&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516677687","title":"Iovance Biotherapeutics, Inc.盘中异动 股价大跌5.07%报3.84美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677687","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516677687?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:39","pubTimestamp":1741099151,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时39分，Iovance Biotherapeutics, Inc.股票出现波动，股价急速跳水5.07%。Iovance Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.12%。Iovance Biotherapeutics, Inc.公司简介：Iovance Biotherapeutics Inc 是一家临床阶段的生物制药公司，通过利用人体免疫系统识别和摧毁多种癌细胞的能力，为每位患者提供个性化治疗，开创了治疗癌症的变革性方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223912989bae64&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223912989bae64&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IOVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152554288","title":"异动解读 | Iovance Biotherapeutics股价盘中暴跌27.66%,分析师下调目标价引发担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1152554288","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152554288?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:43","pubTimestamp":1740753780,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics(IOVA.US)周五股价盘中大跌27.66%,引发广泛关注。\n\n导致股价暴跌的主要原因是,Baird分析师下调了IOVA的目标股价。Baird维持IOVA的优于大市评级不变,但将其目标价从24美元下调至20美元。\n\n分析师下调目标价反映出外界对该公司前景的担忧。作为一家细胞疗法生物科技公司,Iovance Biotherapeutics致力于开发创新的癌症免疫疗法产品。分析师对公司后续药品管线以及销售增长潜力的预期可能较暗淡。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186787959","title":"异动解读 | Iovance Biotherapeutics (IOVA)盘前暴跌26.24%,安银下调目标价或为主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1186787959","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186787959?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:34","pubTimestamp":1740753296,"startTime":"0","endTime":"0","summary":"生物科技公司Iovance Biotherapeutics (IOVA.US)今日盘前股价大跌26.24%,引发市场关注。\n\n消息面上,资深投行Baird周四晚间下调了IOVA的目标价,由24美元下调至20美元,或许是导致这一盘前暴跌的主要原因。\n\n尽管Baird仍然维持IOVA \"优于大市\"的投资评级不变,但下调目标价反映了分析师对该公司未来业绩预期的担忧。IOVA目前正在开发针对多种癌症的临床晚期新型免疫疗法,处于重要阶段,后续的数据和监管审批结果将决定公司前景。而目标价下调无疑在一定程度上打击了投资者的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | Iovance Biotherapeutics (IOVA)盘前暴跌26.24%,安银下调目标价或为主因","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514278327","title":"Baird：维持Iovance Biotherapeutics(IOVA.US)评级，由优于大市调整至优于大市评级, 目标价由24.00美元调整至20.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514278327","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514278327?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:28","pubTimestamp":1740752883,"startTime":"0","endTime":"0","summary":"Baird：维持Iovance Biotherapeutics(IOVA.US)评级，由优于大市调整至优于大市评级, 目标价由24.00美元调整至20.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28222848467015.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514535563","title":"Iovance Biotherapeutics(IOVA.US)：2024年Q4财报实现营收7369.4万美元，前值为48.2万美元，预期值为7217万美元；每股收益为-0.26美元，前值为-0.45美元，预期值为-0.27美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514535563","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514535563?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:21","pubTimestamp":1740691300,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics(IOVA.US)：2024年Q4财报实现营收7369.4万美元，前值为48.2万美元，预期值为7217万美元；每股收益为-0.26美元，前值为-0.45美元，预期值为-0.27美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28052148442324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127368942","title":"Iovance Biotherapeutics 2024年第四季度GAAP每股亏损$(0.26)好于预期$(0.27)，销售额$7370万好于预期$7239.3万","url":"https://stock-news.laohu8.com/highlight/detail?id=1127368942","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127368942?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:10","pubTimestamp":1740690649,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics  报告称，季度每股亏损$，好于分析师一致预期的$，增幅为3.7%。这比去年同期的$每股亏损增加了42.22%。这比去年同期的$482.000千销售额增加了15.19千百分比。以上内容来自Benzinga Earnings专栏，原文如下：Iovance Biotherapeutics  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 3.7 percent. This is a 42.22 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $73.700 million which beat the analyst consensus estimate of $72.393 million by 1.81 percent.  T","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Iovance Biotherapeutics 2024年第四季度GAAP每股亏损$(0.26)好于预期$(0.27)，销售额$7370万好于预期$7239.3万","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2514438576","title":"Iovance Biotherapeutics, Inc.盘中异动 股价大涨5.05%报5.62美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514438576","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514438576?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:36","pubTimestamp":1740666970,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时36分，Iovance Biotherapeutics, Inc.股票出现异动，股价大幅拉升5.05%。Iovance Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.79%。Iovance Biotherapeutics, Inc.公司简介：Iovance Biotherapeutics Inc 是一家临床阶段的生物制药公司，通过利用人体免疫系统识别和摧毁多种癌细胞的能力，为每位患者提供个性化治疗，开创了治疗癌症的变革性方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223610a2567b39&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223610a2567b39&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IOVA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.iovance.com","stockEarnings":[{"period":"1week","weight":0.1855},{"period":"1month","weight":0.5916},{"period":"3month","weight":1.1595},{"period":"6month","weight":1.784},{"period":"1year","weight":2.0731},{"period":"ytd","weight":1.9267}],"compareEarnings":[{"period":"1week","weight":-0.0044},{"period":"1month","weight":0.0363},{"period":"3month","weight":0.0355},{"period":"6month","weight":0.1155},{"period":"1year","weight":0.202},{"period":"ytd","weight":0.1278}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Iovance Biotherapeutics, Inc.是一家新兴的生物技术公司，专注于培养细胞，使用自体肿瘤浸润淋巴细胞（TIL）治疗转移性黑色素瘤等实体瘤的细胞治疗方法的发展和商业化。该公司于2007年9月17日在内华达州成立。","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.029113},{"month":2,"riseRate":0.545455,"avgChangeRate":0.158395},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.048412},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.016024},{"month":5,"riseRate":0.416667,"avgChangeRate":-0.065253},{"month":6,"riseRate":0.5,"avgChangeRate":0.132853},{"month":7,"riseRate":0.666667,"avgChangeRate":0.041289},{"month":8,"riseRate":0.416667,"avgChangeRate":0.080069},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.078972},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.022017},{"month":11,"riseRate":0.727273,"avgChangeRate":0.07065},{"month":12,"riseRate":0.636364,"avgChangeRate":0.051779}],"exchange":"NASDAQ","name":"Iovance Biotherapeutics, Inc.","nameEN":"Iovance Biotherapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Iovance Biotherapeutics, Inc.(IOVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Iovance Biotherapeutics, Inc.(IOVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Iovance Biotherapeutics, Inc.,IOVA,Iovance Biotherapeutics, Inc.股票,Iovance Biotherapeutics, Inc.股票老虎,Iovance Biotherapeutics, Inc.股票老虎国际,Iovance Biotherapeutics, Inc.行情,Iovance Biotherapeutics, Inc.股票行情,Iovance Biotherapeutics, Inc.股价,Iovance Biotherapeutics, Inc.股市,Iovance Biotherapeutics, Inc.股票价格,Iovance Biotherapeutics, Inc.股票交易,Iovance Biotherapeutics, Inc.股票购买,Iovance Biotherapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Iovance Biotherapeutics, Inc.(IOVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Iovance Biotherapeutics, Inc.(IOVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}